Bentazepam[1] (also known as Thiadipone, Tiadipona) is a thienodiazepine which is a benzodiazepine analog.[2]
Clinical data | |
---|---|
Trade names | Tiadipona (ES) |
AHFS/Drugs.com | International Drug Names |
Routes of administration | Oral (tablets) |
ATC code |
|
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Metabolism | Hepatic |
Elimination half-life | 2–4 hours |
Excretion | Renal |
Identifiers | |
| |
CAS Number |
|
PubChem CID |
|
ChemSpider |
|
UNII |
|
KEGG |
|
ChEMBL |
|
CompTox Dashboard (EPA) |
|
ECHA InfoCard | 100.123.659 |
Chemical and physical data | |
Formula | C17H16N2OS |
Molar mass | 296.39 g·mol−1 |
3D model (JSmol) |
|
| |
| |
(what is this?) (verify) |
It possesses anxiolytic, anticonvulsant, sedative and skeletal muscle relaxant properties. Peak plasma rates are achieved in around 2,5 hours after oral administration.[3] The elimination half-life is between approximately 2–4 hours.[2][4] Bentazepam is effective as an anxiolytic.
A severe benzodiazepine overdose with bentazepam may result in coma and respiratory failure.[5] Adverse effects include dry mouth, somnolence, asthenia, dyspepsia, constipation, nausea[6] and drug-induced lymphocytic colitis has been associated with bentazepam.[7][8] Severe liver damage and hepatitis has also been associated with bentazepam.[9][10][11] Whilst liver failure from bentazepam is considered to be rare, liver function monitoring has been recommended for all patients taking bentazepam.[12]